Background Many patients (patients) with epidermal growth factor receptor mutation-positive
(EGFR M+) non-small-cell lung cancer (NSCLC) respond to the EGFR tyrosine kinase …

Methods This open label, single-arm, multi-centre, investigator-initiated, phase 2,
cooperative group trial included adults with metastatic, EGFR-mutated NSCLC with an …

Introduction EGFR tyrosine kinase inhibitors (TKIs) are recommended for EGFR-mutated
NSCLC treatment. EGFR activation up-regulates programmed death-ligand 1 expression …

Background Based on the result of the FLAURA trial, osimertinib (OSI) is a standard of care
in patients (pts) with previously untreated EGFR-mutated advanced non-small cell lung …

Background This study aimed to investigate the efficacy of immunotherapy, as monotherapy
or in combination, comparing to chemotherapy with or without anti-angiogenesis for …

Background In RELAY, a dose of RAM 10 mg/kg every 2 weeks (Q2W) was selected based
on exposure-response analysis, using data from second-line (2L) phase 3 studies …

Methods In this multi-center, randomized, controlled comparative, phase II trial, patients from
10 sites in China, with EGFR wild-type NSCLC progressing after 1st-line platinum-based …

Historically, non-small cell lung cancer (NSCLC) is divided into squamous and
nonsquamous subtypes based on histologic features. With a growing number of oncogenic …

Simple Summary The addition of bevacizumab or ramucirumab to systemic therapy for
EGFR-mutated non-small-cell lung cancer (NSCLC) patients provides survival benefits. No …

Background Amivantamab (ami) is an EGFR-MET bispecific antibody with immune cell-
directing activity. In MARIPOSA-2 (NCT04988295), ami plus carboplatin-pemetrexed (ami …